Prior Authorization AI Buyer Checklist for Healthcare

Prior Authorization AI Buyer Checklist for Healthcare

Use this checklist before a request for information, a vendor demo, a shortlist, or a pilot proposal. Its job is to determine whether the buying problem, scope, owners, evidence requests, and mandatory referrals are complete enough to enter the next review stage.

The output is a buyer-owned procurement packet, not a vendor ranking. Completing the packet does not approve a supplier, establish legal applicability, validate a product, authorize clinical or operational use, or permit production deployment.

Start with the local workflow and a no-buy alternative. A polished demonstration should not become the reason to purchase. If the organization cannot name the problem, the affected requests, the authoritative records, and the person accountable for the decision, the process should stop before supplier comparison.

This guide is for healthcare technology research and procurement planning. It is not medical, clinical, legal, billing, coding, reimbursement, security, or compliance advice. Qualified local owners must determine which requirements apply and whether evidence is sufficient for the proposed setting.

Run the six gates in order. Later evidence depends on earlier scope. A security report cannot prove that the correct workflow is being evaluated, and projected savings cannot cure an unresolved authority, privacy, data-integrity, or recovery problem.

Gate 1: prove the buying problem and no-buy baseline

Describe the current prior authorization process without vendor language. Identify where coverage requirements are found, who gathers documentation, how requests are submitted, where responses arrive, how missing information is corrected, how denials and appeals are routed, and how authorization status and expiration are reconciled.

Define the decision the organization is trying to improve. Examples may include reducing avoidable rework, making request status visible, or improving documentation completeness. These are questions to investigate, not claims that a tool will deliver the outcome.

Record the no-buy baseline. Process redesign, staffing, payer-specific education, template changes, queue management, or existing EHR capabilities may address part of the problem without acquiring a new product.

Evidence request:

• A current-state workflow map with source systems, handoffs, queues, and exception paths.
• A reproducible baseline with source, period, numerator, denominator, exclusions, and owner.
• Documented burden or risk tied to the proposed scope, including patient and staff effects.
• Existing controls, available system capabilities, and the no-buy alternative.
• A named sponsor, workflow owner, desired decision, and stop trigger.

Stop rule: stop when the team cannot reproduce the problem, distinguish it from a staffing or process issue, identify an accountable owner, or explain why a purchase review is the appropriate next action.

Gate 2: bound scope, applicability, and accountable authority

Define whether the buyer is a provider, payer, or another entity and record the program, line of business, request type, service, drug or non-drug boundary, location, channel, language, user role, population, and systems in scope. List exclusions with equal precision.

Map the people who can approve the procurement stage, determine regulatory or contractual applicability, review clinical or operational impact, accept residual risk, pause the process, and authorize the next stage. A committee name without an accountable role is incomplete.

For every external requirement, preserve the source, status, version, and observed date. A narrow rule or program decision must not be reused as a universal requirement for every payer, request, product, or jurisdiction.

Evidence request:

• An included-and-excluded scope statement covering entity, program, payer, service, request, location, channel, user, and population.
• An applicability ledger with source, final or proposed status, version, observed date, rationale, and qualified owner.
• A decision-authority matrix for business, clinical, operational, technical, privacy, security, legal, compliance, finance, and procurement roles.
• A list of decisions that remain with clinicians, utilization management, payer staff, or other authorized people.
• A review-expiry date and the change events that reset the scope decision.

Stop rule: stop when the buyer cannot bound the use, name the authority for a material decision, resolve a critical applicability question, or prevent a narrow approval from expanding silently.

Gate 3: map workflow, data, and human authority

Trace requirement discovery, documentation assembly, submission, request-for-information handling, approval or denial response, appeal handoff, authorization expiration, and status reconciliation. Name the authoritative system and owner at every transition.

Map patient, payer, order, diagnosis, clinical-documentation, attachment, response-reason, timestamp, authorization, audit, support, and telemetry data. Record which fields are authoritative, derived, correctable, retained, exported, or deleted and which entities or subprocessors can access them.

Human review is a control only when the reviewer has the evidence, time, competence, authority, correction path, and escalation route needed to act. Labels such as assistive or human in the loop do not establish that the operating design works.

Evidence request:

• An end-to-end workflow and state map, including ordinary, exception, appeal, downtime, and reconciliation paths.
• A field-level data-flow record with entity, purpose, access, location, retention, deletion, and system of record.
• A human-authority map showing review evidence, override, disagreement, correction, pause, escalation, and restart authority.
• Examples of missing, conflicting, wrong-patient, wrong-plan, duplicate, late, or stale information and their expected handling.
• A record-preservation and correction plan for affected requests and downstream systems.

Stop rule: stop when sensitive data movement is unknown, an authoritative source cannot be named, a material error cannot be detected or corrected, or the buyer cannot pause and reconcile the workflow without an undocumented dependency.

Gate 4: issue a versioned minimum evidence request

Translate each procurement requirement into an evidence request before viewing supplier results. Record why the requirement matters, the exact product or module, version or configuration, proposed context, evidence class, limitation, buyer verifier, observed date, expiry, and next action.

Keep source verified, supplier documented, and buyer observed evidence separate. A roadmap, demonstration, badge, case study, or supplier statement may justify further review, but it is not a locally observed result.

Ask for negative results, exclusions, known deviations, unresolved defects, and change history alongside favorable material. Evidence that cannot be tied to the proposed version and setting remains contextual.

Evidence request:

• A requirement-to-evidence register with stable identifiers and named buyer verifiers.
• Product, module, integration, model or ruleset, configuration, and release identifiers when applicable.
• Methods, cohort, payer or program, workflow, comparator, exclusions, limitations, and observed dates behind material claims.
• Configured evidence for interfaces, access, logging, correction, exceptions, support, recovery, export, and deletion.
• Change-notice, regression, renewal, and evidence-expiry commitments.

Hold rule: hold when a material claim has no traceable source, the evidence concerns a different version or context without justification, limitations are withheld, or the supplier asks the buyer to treat a demo as validation.

Gate 5: refer mandatory depth reviews before comparison

The checklist identifies required specialist reviews; it does not pretend to complete them. Create a referral for privacy and security, interoperability, clinical and operational integrity, legal and compliance, commercial and exit terms, economic evaluation, and pilot readiness when those areas apply.

Each referral needs a hard-stop question, accountable owner, expected artifact, dependency, due date, status, limitation, and residual risk. A linked document is not enough unless the responsible buyer owner verifies that its scope matches the proposed service and configuration.

Material failures in scope, authority, privacy, security, data integrity, exception handling, or recovery cannot be offset by a total score, feature breadth, speed, price, projected savings, or a favorable demonstration.

Evidence request:

• A mandatory-review register covering privacy, security, interoperability, clinical, operational, compliance, commercial, economic, pilot, and exit responsibilities.
• The specialist owner and artifact required to close each material question.
• The exact proposed product, service, region, interface, data flow, and contract scope addressed by each review.
• Open findings, failed controls, compensating measures, due dates, residual risk, and acceptance authority.
• A documented rule for which failures force stop or hold before vendor comparison.

Stop rule: stop when a material specialist review has no owner, a hard-stop question remains open or failed, the evidence is out of scope, or a projected benefit is being used to bypass the required review.

Gate 6: record the stage decision and handoff

Hold a buyer-owned decision meeting rather than allowing a supplier presentation to become the decision record. Preserve the approved scope, excluded uses, evidence classes, complete and incomplete items, conditions, disagreements, failures, next owner, deadline, and expiry.

Use four stage decisions: stop, hold, advance, and advance with conditions. Advance means the packet is sufficient to enter a named next review stage. It does not authorize purchase, deployment, or go-live.

Make conditional decisions expire. Each condition needs an owner, action, deadline, interim control, required evidence, and expiry. If the evidence does not arrive by the deadline, return the item to incomplete or open/failed instead of extending permission silently.

Evidence request:

• A signed stage-decision record with scope, exclusions, decision, rationale, dissent, approver, and observed date.
• A list of complete, incomplete, conditional, and not applicable with rationale items.
• Failed and open evidence with named owners, actions, deadlines, interim controls, and expiry.
• The next team, decision page, required inputs, and questions that remain outside this checklist.
• Review-reset triggers covering payer, program, service, rule, product, version, integration, supplier, data, and contract changes.

Hold rule: hold when the decision cannot be reconstructed, a condition has no owner or expiry, the next stage is unnamed, or the record implies approval beyond the evidence reviewed.

Questions by accountable owner

Prior authorization operations and utilization management

• In which payer, line of business, request, service, and exception paths does the current problem occur, and what evidence shows it merits a purchase review?
• Which system and person retain authority for requirements, documentation, submission, response, appeal, expiration, and status reconciliation?
• Which scopes and failure paths are excluded, and what condition forces the team to stop instead of continuing a demo?

Integration, privacy, and security owners

• Through which systems, entities, and subprocessors do PHI, ePHI, rules, attachments, responses, and logs move, and which records are authoritative?
• Why do CMS, business associate, BAA, HTI-1, API, standard, or other requirements apply or not apply, and where are source, status, version, and date recorded?
• Which interface, access, logging, downtime, recovery, correction, export, and deletion evidence is required before cross-vendor comparison?

Clinical, compliance, and patient-impact owners

• Which outputs could affect clinical or operational action, documentation integrity, patient delay, notice, appeal, accessibility, or language access, and who can disagree or pause?
• Which ordinary, boundary, missing-data, wrong-patient, wrong-plan, denial, more-information, downtime, and recovery scenarios are hard-stop tests?
• How will complaints, harm, near misses, corrections, and patient or staff burden reach accountable owners rather than disappear inside throughput averages?

Procurement, finance, and executive owners

• Which claims remain a roadmap, demo, or supplier assertion, and which have source-verified or buyer-observed support?
• Which implementation, support, contract, renewal, exit, unpriced labor, pricing, ROI, and pilot questions must be handed to specialist owners?
• Who may stop, hold, advance, or advance with conditions, when do conditions expire, and which changes reset the decision?

Six buyer-owned artifacts

The buyer should own the packet even when suppliers provide source material. Every artifact keeps an evidence link, source or version, observed date, owner, limitation, and next action. Preserve failed and inconclusive findings so another reviewer can reconstruct the decision.

A. Procurement charter and no-buy baseline

Record the problem, current workflow, affected users and patients, baseline source and period, no-buy alternative, desired decision, sponsor, workflow owner, and stop trigger.

• Separate observed burden from assumptions.
• Record numerator, denominator, exclusions, and source for any baseline.
• List existing process and system options before proposing acquisition.
• State what evidence would show that no purchase is needed.

B. Scope, applicability, and owner matrix

Record entity, program, line of business, payer, drug or non-drug boundary, request, service, population, location, channel, language, users, systems, included scope, exclusions, and accountable owners.

• Link every material applicability conclusion to its source or version.
• Preserve final or proposed status and observed date.
• Name the owner qualified to decide applicability.
• Set an expiry and review-reset trigger.

C. Workflow, data, and authority map

Record the trigger, requirement source, documentation, submission and response states, appeal handoff, expiration, reconciliation, data fields, systems of record, human authority, correction, pause, escalation, and restart path.

• Include ordinary and exception paths.
• Show PHI and ePHI movement through subprocessors and support systems.
• Identify derived data and correctable records.
• Preserve the evidence required to reconstruct an affected request.

D. Requirement-to-evidence request register

Give every requirement a stable identifier. Record why it is needed, the supplier response, product or module, version, evidence class, context, evidence link, buyer verifier, limitation, observed date, expiry, status, and next action.

• Do not turn supplier documented evidence into buyer observed evidence.
• Keep roadmap and demonstration claims labeled as assertions.
• Retain exclusions, negative results, and known deviations.
• Reopen evidence after a material version or configuration change.

E. Mandatory review and referral register

Record each specialist area, hard-stop question, owner, target artifact, dependency, due date, status, open finding, residual risk, limitation, and next action.

• Include privacy, security, interoperability, clinical, operational, legal, compliance, commercial, economic, pilot, and exit referrals as applicable.
• Confirm that the reviewed product, service, region, configuration, and data flow match the proposal.
• Keep material failed or open items visible.
• Do not replace specialist review with a document count.

F. Stage decision and handoff record

Record stop, hold, advance, or advance with conditions; the bounded scope; complete and incomplete items; conditions; failed and open evidence; dissent; approver; next owner; deadline; expiry; and review trigger.

• State exactly which next stage is allowed.
• State which decisions remain outside the record.
• Make every condition expire and return to incomplete if unmet.
• Preserve why the buyer stopped, held, or advanced.

Evidence, item, and stage-decision rules

Use evidence classes to describe provenance, item states to describe checklist completion, and stage decisions to describe what review may happen next. Do not collapse them into one score.

• source verified means the buyer checked the identified authoritative source, version, status, and observed date.
• supplier documented means the supplier provided a traceable statement or artifact that the buyer has not observed locally.
• buyer observed means the buyer recorded what happened in the proposed configuration and bounded test context.
• open/failed means required evidence is absent, contradictory, out of scope, expired, or did not meet the recorded condition.
• complete means the required evidence and accountable decision are present for the bounded item.
• incomplete means a required field, artifact, owner, or decision is missing.
• conditional means an interim decision has an owner, action, deadline, control, evidence requirement, and expiry.
• not applicable with rationale means a qualified owner documented why the item does not apply, with source and review trigger.
• stop ends the current procurement path until a new charter or materially different scope is approved.
• hold pauses advancement while named evidence or ownership gaps are resolved.
• advance permits entry to one named next review stage.
• advance with conditions permits that named stage only within documented controls and expiry.

No blank item becomes a pass. No default weight or total score can override a material hard stop. A stage decision does not authorize purchase, deployment, or go-live and does not replace a later clinical, legal, compliance, security, financial, contracting, implementation, or pilot decision.

Current, proposed, and conditional boundaries

The CMS-0057-F fact sheet identifies impacted payers and distinguishes process provisions generally beginning in 2026 from API requirements generally beginning in 2027. Its prior authorization API scope concerns non-drug items and services. The buyer must still confirm the applicable payer, program, request, date, and exception.

The 2026 CMS proposed rule fact sheet describes proposed extensions involving drugs, standards, attachments, and metrics. For this checklist, drug prior authorization remains proposed within that cited rulemaking context and must not be presented as a finalized universal requirement. Record source, status, version, and observed date.

The CMS process FAQ describes reporting levels, periods, request-count details, and continuing clinical review for some complex decisions. An aggregate CMS metric does not prove vendor performance or establish a local baseline.

The CMS electronic prior authorization overview supports asking about EHR and vendor roadmaps, API capability, upgrades, testing, training, support, and payer pilots. These are readiness questions, not a product certification or a substitute for configured workflow and exception evidence.

The HHS business associate guidance supports a fact-specific review of covered entities, business associate relationships, BAA duties, subprocessors, and listed exceptions. A BAA is not automatically required for every provider-payer exchange, and a signed agreement does not complete workflow or security review.

The HHS risk-analysis guidance describes risk analysis as foundational for ePHI safeguards and rejects a one-size-fits-all method. It does not certify a supplier or prove that controls operate in the proposed environment.

The HTI-1 final rule page provides algorithm-transparency context for certified health IT and relevant predictive decision support interventions. HTI-1 does not automatically cover every prior authorization tool, rules engine, or AI function; record certification, module, and function applicability first.

The NIST AI Risk Management Framework and AI RMF 1.0 support voluntary, continuous Govern, Map, Measure, and Manage work. The NIST CSF 2.0 release supports Govern, Identify, Protect, Detect, Respond, and Recover outcomes. These frameworks are voluntary and are not a compliance certificate, product approval, or universal passing threshold.

FAQs

Does completing this checklist approve a vendor?

No. It shows whether a buyer-owned procurement packet is complete enough to enter a named next review stage. Vendor selection, contracting, specialist review, pilot acceptance, implementation, and go-live remain separate decisions.

Does a roadmap or demo close an evidence request?

No. A roadmap or demo is supplier documented evidence about a claim. The buyer should preserve the exact product, module, version, context, limitation, and promised date, then define what source verification or buyer-observed evidence is still required.

Does a BAA complete privacy and security review?

No. First determine whether a business associate relationship applies. When a BAA is required, it records duties for that relationship; it does not prove data minimization, configured access, retention, deletion, incident handling, workflow integrity, or recovery.

Do CMS aggregate metrics prove vendor impact?

No. Preserve payer and reporting level, period, request-count method, numerator, denominator, unit, appeals treatment, and limitations. Those metrics provide external context and do not establish supplier attribution or the buyer's local baseline.

Does HTI-1 apply to every prior authorization AI tool?

No. Start with whether the relevant function is part of certified health IT and within the applicable predictive decision support scope. The rule page is not universal certification for every product or workflow.

When should the buyer stop or hold the process?

Stop when the buying problem, bounded scope, decision authority, or safe path cannot be established. Hold when material evidence, ownership, specialist review, correction, exception, recovery, or contract questions have named work remaining and cannot safely advance.

Handoff to adjacent decision pages

This checklist establishes procurement completeness and does not complete their reviews.

• Use prior authorization AI tools for candidate discovery after the buying problem and minimum qualifications are defined.
• Use the prior authorization vendor evaluation guide for same-scope cross-vendor comparison and an evidence-backed selection record.
• Use the prior authorization workflow implementation guide for the configured workflow, cutover, downtime, rollback, reconciliation, and monitoring after selection.
• Use the prior authorization security review and compliance questions for security and compliance deep review.
• Use the prior authorization pricing questions and ROI model for commercial and economic inputs without allowing price or projected value to override hard stops.
• Use the prior authorization pilot planning guide for local pilot execution, cohort, baseline, scenarios, acceptance criteria, staffing, stop rules, and exit.

Evidence boundary

This page converts official source boundaries into an editorial procurement structure. The six gates, artifacts, states, and stage decisions are HealthAIdir's buyer-oriented design; they are not a CMS, HHS, ASTP, or NIST form.

No product testing, customer interview, local performance measurement, price benchmark, legal determination, clinical review, or compliance approval is claimed. Supplier claims remain supplier documented until the buyer records stronger evidence in the proposed context.

Use qualified clinical, operational, privacy, security, legal, compliance, finance, procurement, and technical owners for the decisions they are authorized to make. Record uncertainty and limitations instead of converting missing evidence into approval.

Continue your HealthAIdir research

• Map the local workflow with AI for prior authorization.
• Turn requirements into owned questions with the Healthcare AI Vendor Readiness Checker.
• Review prior authorization, payer-provider workflow, audit log, and revenue cycle management.
• Keep a link to the source, version, observed date, owner, limitation, and next action for every material conclusion.